Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beremagene Geperpavec: First Approval.

Drugs - 1 Aug 2023

Dhillon Sohita

Abstract excerpt

Beremagene geperpavec-svdt (VYJUVEK™) is a topically applied, redosable, live, replication defective herpes simplex virus-1 (HSV-1) vector -based gene therapy that is being developed by Krystal Biotech to deliver functional human collagen type VII alpha 1 chain (COL7A1) genes in patients with both, dominant and recessive dystrophic epidermolysis bullosa. Beremagene geperpavec can transduce both keratinocytes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Collagen
Share to Collagen Type VII
Share to Epidermolysis Bullosa Dystrophica

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Keratinocytes

Share to Mutation

Source

Identifiers

PMID: 37432558
DOI: 10.1007/s40265-023-01921-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beremagene Geperpavec: First Approval.PMID 37432558Read ↗

Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosaSemantic proximity Read ↗

Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.Semantic proximity Read ↗

Gene Therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin GraftsSemantic proximity Read ↗

Treatment of Epidermolysis Bullosa and Future Directions: A ReviewSemantic proximity Read ↗

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosaSemantic proximity Read ↗

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.Semantic proximity Read ↗

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

EB2017-Progress in Epidermolysis Bullosa Research toward Treatment and Cure.Semantic proximity Read ↗

COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.